로딩 중…
지수 로딩 중…
HK inno.N Corporation
195940· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩34,450+0.58%
2026-11-02
Financials
Valuation Metrics
HK inno.N Corporation's Market Cap is ₩9760B. At end of 2025 it was ₩1.4T. Ranked #297 of 2,410 in KR market (top 12%), #80 of 1,631 on KOSDAQ (top 5%), #31 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 13%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 975.96B KRW | KR#297/2,410 Sec#31/231 |
| Revenue | 1.08T KRW | KR#390/2,410 Sec#12/231 |
| Net Income | 85.85B KRW | KR#275/2,410 Sec#15/231 |
| Total Assets | 2.02T KRW | KR#305/2,410 Sec#12/231 |
| Net Assets | 1.35T KRW | KR#234/2,410 Sec#11/231 |
| Employees | 1,721 | KR#161/2,410 Sec#8/231 |
| Value | ||
| P/E | 11.37x | KR#938/2,410 Sec#50/231 |
| P/B | 0.72x | KR#1,232/2,410 Sec#71/231 |
| PEG | 0.32x | KR#651/2,410 Sec#38/231 |
| P/S | 0.90x | KR#1,377/2,410 Sec#79/231 |
| EV/EBITDA | 10.36x | KR#678/2,410 Sec#32/231 |
| FCF Yield | 8.96% | KR#678/2,410 Sec#29/231 |
| Profitability | ||
| ROE | 6.36% | KR#943/2,410 Sec#66/231 |
| ROA | 4.24% | KR#825/2,410 Sec#66/231 |
| Op. Margin | 11.98% | KR#423/2,410 Sec#36/231 |
| Revenue Growth | 10.55% | KR#867/2,410 Sec#83/231 |
| Earnings Growth | 35.95% | KR#616/2,410 Sec#40/231 |
| Financial Health | ||
| Debt Ratio | 49.74% | KR#954/2,410 Sec#110/231 |
| Total Debt | 430.80B KRW | KR#335/2,410 Sec#11/231 |
| FCF | 87.49B KRW | KR#215/2,410 Sec#12/231 |
| Cash | 68.25B KRW | KR#617/2,410 Sec#32/231 |
| Current Ratio | 0.89x | KR#1,843/2,410 Sec#179/231 |
| Net Debt/EBITDA | 2.81x | KR#902/2,410 Sec#65/231 |
| Dividend | ||
| Div. Yield | 1.19% | KR#1,105/2,410 Sec#62/231 |
| Div. Growth | 17.14% | KR#483/2,410 Sec#27/231 |
| Performance | ||
| 1Y Return | -30.26% | KR#1,441/2,410 Sec#112/231 |
| 1M Return | -14.20% | KR#1,449/2,410 Sec#149/231 |
| From 52W High | -41.21% | KR#789/2,410 Sec#56/231 |
| 1Y MDD | -43.14% | KR#680/2,410 Sec#47/231 |
| Trading | ||
| Volume | 50,362 shares | KR#829/2,410 Sec#85/231 |
| Trading Value | 1.72B KRW | KR#398/2,410 Sec#40/231 |
| Foreign Own. | 11.94% | KR#416/2,410 Sec#33/231 |
| Per Share | ||
| EPS | 3,030 KRW | KR#337/2,410 Sec#21/231 |
| BPS | 47,678 KRW | KR#273/2,410 Sec#18/231 |
Company Info
동사는 2014년 씨제이제일제당㈜의 제약사업부문 물적분할로 설립되어 2018년 한국콜마㈜에 인수됨. 전문의약품 제조판매업 등 ETC사업부문과 음료수 제조업 등 H&B사업부문으로 구분되며, 다양한 의약품과 원료의약품을 국내외 판매하고 있음. 신약 케이캡, 로바젯 등 핵심 제품을 보유하고 있으며, 암, 소화, 당뇨 같은 혁신적 파이프라인을 확보하며 발전시키고 있음. HK이노엔는 2014년에 설립되었으며 충청북도 청주시에 본사를 두고 있습니다.